Last Updated on November 11, 2024 by The Health Master
The pharmaceutical company said that the United States Food and Drug Administration (USFDA) had conducted a good manufacturing practices (GMP) plus pre-approval inspection of Piramal Pharma’s Pithampur facility from 15 May 2023 to 19 May 2023.
The inspection was completed successfully with ‘zero’ Form – 483 observations and no action indicated (NAI) designation.
“The company remains committed to maintain the highest standards of compliance,” Piramal Pharma said in a statement.
Piramal Pharma is a pharmaceutical company that manufactures and develops a wide range of pharmaceutical solutions to reduce diseases. Piramal Pharma serves customers worldwide.
The pharmaceutical company reported a consolidated net loss of Rs 90 crore in Q3 December 2022 as against a net profit of Rs 163.37 crore in the year-ago period.
Revenue from operations rose by 11% year-on-year to Rs 1,716 crore in Q3 FY23 from Rs 1,539 crore in the year-ago period.
USFDA issues Form 483 with 4 observations to Aurobindo Pharma
USFDA issues Form 483 with zero observations to Pharma MSMEs: Gujarat
USFDA issues Form 483 with 3 observation to Zydus, Ahmedabad
USFDA issues Form 483 with zero observation to Piramal
USFDA issues Form 483 with 10 observations to Lupin, Pithampur
USFDA issues Form 483 with 2 observations to Alembic, Gujarat
Pharma Industry urge NPPA to adopt Prospective Batch Pricing to reduce overcharging
Govt to amend Cosmetics Rules 2020 to strengthen Regulation & Quality control
The Effectiveness of 70% Alcohol as a Disinfectant
Drug recall: Pediatric Drops recalled due to this reason
Govt strict on failure of samples of medicines
USFDA issues Form 483 with 4 observations to Aurobindo Pharma
NPPA fixed Ceiling price of 5 scheduled formulations: May 2023
NPPA revised Ceiling price of 15 scheduled formulations: May 2023
